Four Sri Lankan defensive conglomerates — which one screens cleanest?
A side-by-side side-by-side comparison of Hemas (HHL), Sunshine (SUN), Melstacorp (MELS) and CIC Holdings — the four diversified conglomerates investors most often bucket together for their defensive sector exposure (healthcare, consumer staples, plantations, agri inputs). Three pass the cash-conversion test cleanly. One fails. And one of them recognised a Rs 5.5B bargain-purchase gain on its JKH stake — same accounting playbook as LOLC, just a fraction of the size and properly disclosed as one-off.
Not investment advice. This is personal independent analysis by DamithInvest, prepared for educational and research purposes only. I am not a registered investment advisor or broker under the Securities and Exchange Commission of Sri Lanka. Views expressed are personal observations — positive, neutral and negative language here is analytical, not a buy, sell, or hold recommendation. Do your own research and consult a SEC-registered advisor before making any investment decision.
HHL.N0000
Hemas Holdings
LKR 32.90
−0.30% · Cap 98.5B
SUN.N0000
Sunshine Holdings
LKR 32.00
+0.63% · Cap 63.0B
MELS.N0000
Melstacorp
LKR 183.00
0.00% · Cap 213.1B
CIC.N0000
CIC Holdings
LKR 32.80
−1.80% · Cap 58.6B
Prices: CSE official close · 14:32 · 26 Apr 2026 · cse.lk
KEY OBSERVATION
Three of the four are structurally cleaner than the LOLC group — HHL, SUN and MELS each carry Fitch AAA(lka) or equivalent rating, generate real operating cash flow, and don't rely on one-time gains. The fourth, CIC, is more nuanced: solid agribusiness operating earnings, but its FY23/24 PAT was inflated by a Rs 5.5B one-time bargain-purchase gain on its 7.02% JKH stake — same accounting mechanic as the LOLC bargain-purchase trick, just one-time and properly disclosed. That gain rolled off in FY24/25, which is why CIC's reported PAT looks like a 42% drop. Cash conversion at CIC also fails the standard test (Op CF / PAT ratio of 0.67×), separating it from the other three. The spider chart below makes the trade-offs visible at a glance.
§01
Are these really the same sector?
Common ask · short answer = no
Investors often bucket HHL, SUN, MELS and CIC together because all four are diversified Sri Lankan family-led holdcos with overlapping defensive exposure. The reality is more nuanced — each has a fundamentally different profit engine:
Group
Real engine
CSE sector
Cash cow segment %
Defensive lens
HHL
Healthcare (pharma + hospitals)
Capital Goods
~60% via Healthcare
Necessity healthcare
SUN
Healthcare + Agri (palm oil)
Food, Beverage & Tobacco
55% Healthcare, 30% Consumer, 15% Agri
Healthcare + necessity consumption
MELS
Beverages (DCSL spirits monopoly)
Food, Beverage & Tobacco
56% Beverages
Sin-stock / monopoly economics
CIC
Crop Solutions + Industrial + JKH stake
Materials (Agri Chemicals)
40% Crop Solutions, 21% Livestock, 17% Health & Personal Care
Agri inputs + necessity consumption
The genuine overlap is healthcare exposure (HHL hospitals + Morison; SUN Healthguard; MELS minimal; CIC Health & Personal Care segment with Vetcare and Pharmaceuticals at Rs 14.5B revenue) and consumer staples (HHL Atlas/Velvet; SUN Watawala/Daintee; CIC's Livestock + Agri Produce). The divergence is sharper: HHL = healthcare-led conglomerate, SUN = agri-consumer-healthcare hybrid with palm oil moat, MELS = essentially a spirits monopoly with hidden Aitken Spence holding, CIC = agribusiness leader (Crop Solutions Rs 32.3B revenue) with a 7.02% John Keells Holdings equity stake that materially distorts reported earnings via equity-method accounting.
§02
The spider chart — six dimensions, four shapes
Normalized 0-100 quality scores
Every metric is scaled to a 0–100 score where higher = better. The shape each company traces tells a different story: SUN's polygon is the largest (best earnings quality & capital efficiency); MELS's is the most lopsided (dominates margin and valuation, weakest defensive profile); HHL is the most balanced; CIC's polygon is visibly the smallest — pulled down by 0.67× cash conversion and beta near 1.
HHL · Hemas
Balanced & defensive
Total area: 67/100 · Strongest on defensive profile, balance sheet
SUN · Sunshine
Largest polygon overall
Total area: 75/100 · Highest earnings quality & capital efficiency
Total area: 45/100 · Fails cash conversion test (0.67×)
Axis
Underlying metric
HHL
SUN
MELS
CIC
Earnings Quality
Op CF ÷ PAT (cap 2.5×)
64
84
44
27
Capital Efficiency
ROE % (cap 25%)
76
94
46
56
Balance Sheet
Inverse D/E (cap 1.5)
87
80
77
54
Operating Margin
EBITDA margin % (cap 35%)
34
51
90
40
Valuation
Inverse EV/EBITDA (cap 15)
58
62
70
56
Defensive Profile
Inverse beta (cap 1.5)
84
81
44
35
◆ HOW TO READ
Each axis runs from 0 (centre) to 100 (outer ring). Higher always means better — for "Valuation" and "Defensive Profile" we invert the underlying metric so cheaper / lower-beta scores higher. The total area enclosed by each polygon roughly indicates overall quality. SUN traces the largest area; CIC the smallest. The shape matters as much as the size — a "spiky" polygon (like MELS) means concentrated strengths; a "round" polygon (like HHL) means balanced quality.
§03
Head-to-head — the raw screen comparison
Quality of earnings · FY24/25 + TTM
Metric
HHL
SUN
MELS
CIC
Best
Revenue FY25 (LKR Bn)
118.0
~60
260.9 / 352.3 TTM
83.3 / 86.1 TTM
MELS scale
EBIT margin FY25
11.6%
16.9%
17.1%
12.5%
SUN/MELS tied
EBITDA margin (TTM)
12.0%
~18%
31.5%
14.1%
MELS dominant
PAT margin FY25
7.1%
10.9%
8.5%
7.6%
SUN highest
ROE FY25
17.7% → 19.0% TTM
23.5%
11.4%
14% (was 28% pre-JKH roll-off)
SUN highest
ROCE / ROIC
25.6% / 13.5%
— / 18.8%
~9-10%
17%
HHL ROCE
Debt/Equity
0.20
0.30
0.35
0.69
HHL cleanest
Net cash position
+LKR 4.7B
+positive
Net debt
Net debt LKR 27.5B
HHL cleanest
Op CF / PAT (FY25)
1.61×
~2.1×
~1.1×
0.67× (9M annualised)
SUN highest
Altman Z-Score
3.35
3.88
N/A
~2.0 (estimated, watch zone)
SUN highest
Piotroski F-Score
7
7
N/A
5-6 (estimated)
HHL/SUN tied
Trailing P/E
11.12x
17.51x
9.57x
10.22x
MELS cheapest
EV/EBITDA
6.30x
5.74x
4.48x
6.54x
MELS cheapest
1-year price change
+62.0%
+44.8%
+31.5%
+46.5%
HHL leading
Dividend yield
3.65%
2.78%
4.92%
1.52%
MELS highest
Beta
0.24
0.29
0.84
0.97
HHL/SUN defensive
Four different stories: HHL is the balance-sheet champion (lowest D/E, AAA, net cash, lowest beta); SUN is the capital-efficiency champion (highest ROE 23.5%, highest ROIC 18.8%, cleanest Z-score); MELS is the cheapness + moat champion (lowest EV/EBITDA 3.8x, highest dividend yield, monopoly economics); CIC is the growth-but-watchlist case — strong revenue growth (+9%) and decent ROCE (17%), but the highest leverage in the group, the worst cash conversion ratio of the four, and a 42% reported PAT decline driven entirely by the FY24 bargain-purchase rolling off.
§04
Company-by-company analysis
4 dossiers · same depth as LOLC piece
HHL.N0000
Hemas Holdings PLCConsumer brands · Healthcare · Mobility · since 1948 · AAA(lka) 6th year
POSITIVE · cleanest balance sheet
Mkt Cap
98.5 B
PE TTM
11.12x
ROE
19.0%
D/E
0.20
Net Cash
+4.7 B
Z-Score
3.35
HHL is the cleanest of the four on a pure accounting basis. FY25 PAT grew 31.9% to LKR 8.34B on revenue that actually fell 3.0% — the margin expansion came from real operational improvement: working-capital optimisation, lower borrowings, and a 60.1% reduction in net finance expenses. Operating cash flow of LKR 13.4B compares favourably to PAT of LKR 8.3B — cash conversion ratio of 161%, which is excellent. Gearing collapsed from 22.4% to 13.5%, net cash position swung from −LKR 0.5B to +LKR 4.7B. Healthcare segment (Rs 70B revenue, Rs 5.8B PBT) is the structural anchor.
▲ Red flags
Consumer Brands revenue down 9.4% — price reductions following Rupee appreciation but volume softness suggests demand-side weakness.
Cyclone Ditwah Q3 FY26 disruption — quarterly earnings down 12.8% YoY; Atlas seasonality shift compounded the impact.
Bangladesh exposure — currency risk and political-economic volatility remain a recurring concern.
Sunshine generates the highest ROE (23.5%) and ROIC (18.8%) of the four. FY25 was a strong year — EBIT Rs 5.5B at a 16.9% margin, PAT Rs 3.6B at 10.9% margin. The Q3 FY26 interim showed a more challenging environment: cumulative 9M PAT down 8.8% YoY to Rs 4.3B as Healthcare EBIT margin compressed from 17.9% to 12.0% (lower government purchase orders for Lina Manufacturing). Notably, Agribusiness EBIT margin expanded from 37.9% to 45.6% — palm oil prices favourable. Strategically, January 2026 acquisition of JAPC expands export-oriented spices and coconut products. IFC invested LKR 3.27B in SHL (Oct 2024) for 14.73% — third-party institutional validation.
▲ Red flags
Q3 FY26 PAT down 8.8% YoY — Rs 4.7B → 4.3B. Healthcare EBIT margin compressed 460bps.
MELS is the largest by market cap (Rs 213.1B) and the cheapest by valuation (PE 9.57x, EV/EBITDA 4.48x). The crown jewel is DCSL — Sri Lanka's dominant spirits monopoly — generating Rs 145B revenue and Rs 27.7B segment profit in FY25. The 31.5% EBITDA margin reflects regulatory-protected oligopoly economics. FY25 PAT surged 75.11% to Rs 22.27B, driven by lower finance costs, divestments of underperforming subsidiaries (Lanka Bell, Texpro, Melsta Labs), and Beverage segment resilience. The hidden value: ~50% stake in Aitken Spence PLC = free exposure to leisure (Heritance), maritime/freight, power. Tourism alone delivered Rs 4.8B PBT in FY25. The single biggest risk is succession + excise tax: Founding Chairman Harry Jayawardena passed Feb 2025; new Executive Chairman is his son Hasitha.
▲ Red flags
Founder succession risk — Deshamanya Harry Jayawardena passed Feb 2025; son Hasitha just took executive chair.
Excise tax sensitivity — DCSL is the cash engine; Sri Lankan government is increasing excise to fund IMF programme.
Lowest ROE of the group (11.4%) — capital tied in low-return plantations and Aitken Spence's modest-margin portfolio.
1 SEVERE warning sign disclosed by GuruFocus.
US 20% tariff exposure — flagged in chairman's letter; Aitken Spence US-bound exports at risk.
Recent restructuring losses — discontinued operations Rs 2.8B PAT loss in FY24. Indicates capital was previously misallocated.
Beverage demand constrained — chairman openly disclosed "consumer demand notably constrained by high taxation."
● Green flags
DCSL is a regulatory-protected spirits oligopoly — 31.5% EBITDA margin is genuine moat economics.
CIC Holdings PLCCrop Solutions · Livestock · Industrial · Health & Personal Care · Agri Produce · since 1964 · 7.02% JKH stake
NEUTRAL with caution · cash conversion concern
Mkt Cap
58.6 B
PE TTM
10.22x
ROE
14% ↓ from 28%
D/E
0.69
Op CF/PAT
0.67×
EV/EBITDA
6.54x
CIC is the most nuanced of the four. The agribusiness operations are genuinely strong — FY25 revenue Rs 83.3B grew 9% YoY, all five segments delivered resilient performance. Crop Solutions (Rs 32.3B revenue, Rs 4.05B segment profit), Livestock Solutions (Rs 14.6B, Rs 1.77B), Industrial Solutions (Rs 6.3B, Rs 1.08B), Health & Personal Care (Rs 14.5B, Rs 2.11B), Agri Produce (Rs 4.6B, Rs 255M). Group operating profit broadly flat at Rs 10.4B. But the headline PAT looks like a 42% drop from Rs 10.97B to Rs 6.33B — and that's almost entirely because of an accounting effect. In October 2023, CIC took a 7.02% stake in John Keells Holdings PLC, applying equity-method accounting from Q3 FY24, which triggered a Rs 5.5B "gain on bargain purchase" in FY23/24. Same accounting mechanic the LOLC group uses, but one-time and properly disclosed. Strip it out and FY24/25 organic profit grew 5%. The cash conversion is the bigger concern: 9M Op CF Rs 4.03B vs PAT Rs 5.97B = 0.67× ratio — significant working-capital build (trade receivables +Rs 6.4B in 9 months). Still recognising small bargain-purchase gains in 9M FY26 (Rs 160M from a smaller equity raise).
▲ Red flags
Op CF / PAT = 0.67× (9M FY26) — only company in the group failing the cash-conversion test. Rs 6.4B receivables build is consuming the cash that should be flowing through.
D/E of 0.69 — highest in the group. Short-term borrowings Rs 32.9B vs cash Rs 5.3B; net debt Rs 27.5B. Significantly more leveraged than HHL (0.20), SUN (0.30) or MELS (0.35).
Rs 5.5B FY23/24 bargain-purchase gain on JKH stake — same accounting mechanic as LOLC but at much smaller scale and disclosed as one-off. The roll-off is why ROE collapsed 28% → 14%.
9M FY26 still recognising bargain-purchase gains — Rs 160M from JKH equity-accounted share issues. Worth monitoring whether this becomes a recurring pattern.
Loss on dilution of JKH investment — Rs 19.81M; CIC did not fully participate in JKH's share-based compensation, diluting effective ownership.
Trade receivables impairment up 210% in 9M FY26 — Rs 195M vs Rs 63M prior. Customer credit quality may be deteriorating.
Q3 FY26 quarterly PAT down 5.0% YoY — Rs 2.86B → 2.72B; revenue grew 10.9% so margin compression is real.
Lower income tax expense growth than PBT growth — tax expense up 22.3% on PBT up 10.2%; effective tax rate rose, hurting bottom line.
P R Saldin (Director) deceased Jan 2026 — minor governance disruption but adds to ongoing succession events.
Concentration in Paints & General Industries (53.31% voting) — single-shareholder dominance.
● Green flags
Group revenue +9% YoY in FY25 to Rs 83.3B — all five segments grew.
CIC owns 7.02% of John Keells Holdings PLC, accounted for under the equity method since Q3 FY24. As at 31 Dec 2025, net assets attributable to CIC Group from JKH = Rs 28.33Bn; investment in equity accounted investees on balance sheet = Rs 33.4Bn. JKH dividend received 9M FY26 = Rs 553M (real cash). The original FY23/24 Rs 5.5B "gain on bargain purchase" came from the difference between CIC's purchase cost and its share of JKH's net assets at acquisition. This is a legitimate IFRS 3 treatment — the same one LOLC uses, but at small scale and as a one-time event. The comparison to LOLC's BIL is the magnitude: BIL recognised Rs 47.6B in such gains, more than 100% of its PBT; CIC's Rs 5.5B was about 40% of FY24 PBT. Concerning but not catastrophic, and the disclosure is honest.
§05
Cash flow reality — the test that separates the four
Operating CF / PAT ratio · key quality test
The single most useful test for accounting quality is Operating Cash Flow ÷ Profit After Tax. A ratio above 1.0× means earnings are backed by real cash; below 1.0× means accruals or working-capital build-up are inflating reported profit. The LOLC group's BIL subsidiary failed this test catastrophically. Here's how the four defensives screen — and CIC is the one that fails:
Company · FY25 / 9M FY26
PAT (LKR Bn)
Op CF (LKR Bn)
Op CF / PAT
Quality signal
HHL · FY25
8.34
13.4
1.61×
Excellent
SUN · FY25 (annualised)
~3.6
~7.7
~2.1×
Excellent
MELS · FY25 (estimated)
22.27
~25
~1.1×
Acceptable
CIC · 9M FY26
5.97
4.03
0.67×
Below threshold — receivables build
BIL (LOLC) — for contrast
57.7
trivial vs PAT
far below 1×
Severe accounting quality flag
Three of four pass cleanly; CIC sits in an awkward middle ground. CIC's 0.67× ratio is not in BIL territory — it's not a sign of fictional earnings. The mechanical reason is clear from the cash-flow statement: trade and other receivables grew by Rs 6.4B in 9M FY26, consuming roughly Rs 1B of "would-have-been" operating cash for every quarter. This can happen for legitimate reasons (rapid growth, agri-cycle seasonality, government tender payment delays) or concerning ones (extending credit to weak customers — which the 210% jump in trade-receivable impairments hints at). It's a flag worth tracking, not a flag worth panicking about.
§06
Where did the money go? — recent capex & investments
FY25 capital deployment · what they bought
● HHL · genuine capacity build
LKR 5.1 Bn capex in FY25
+LKR 2.7 Bn YoY
Hospitals + IT transformation
Rs 1.0B Cath Lab at Hemas Hospital Wattala; Rs 1.9B Thalawathugoda hospital land; SAP RISE platform; Rs 746M solar; Rs 440M R&D. Real productive capacity in healthcare.
● SUN · IFC equity + JAPC bolt-on
JAPC + IFC LKR 3.27B equity
JAPC Jan 2026
Spices + coconut export expansion
January 2026 controlling stake in Joint Agri Products Ceylon. IFC invested LKR 3.27B in Sunshine Healthcare for 14.73% (Oct 2024). Lina Manufacturing capital injection from sister subs. Cinnamon processing centre live.
◆ MELS · capital recycling, mixed quality
Restructuring + LKR 4.27 Bn PPE
3 closures, 1 divestment
Lanka Bell · Texpro · Melsta Labs · Melsta GAMA
Closed loss-making non-core subs. Value-additive cleanup but raises the question: how did these capital allocations happen in the first place?
▲ CIC · the JKH stake dwarfs everything
LKR 17.1 Bn in JKH (cost basis)
7.02% JKH
Carrying value Rs 33.4Bn at 31 Dec 2025
October 2023 strategic investment of Rs 17.1Bn at parent-level for 7.02% of John Keells. Recognised Rs 5.5B bargain-purchase gain in FY24. PPE capex Rs 1.8B in 9M FY26 (modest); biological assets Rs 374M; further investment in associate Rs 3.31B in 9M (top-up to JKH stake). The JKH stake is now larger than any operating segment in CIC.
Capital deployment quality varies meaningfully. HHL's is the most predictable — incremental healthcare capacity in proven categories. SUN's is the most strategic — IFC equity + JAPC export pivot. MELS is defensive cleanup. CIC's biggest capital decision in years was the JKH stake — and that's worth watching closely. JKH is itself a quality holdco with diversified businesses, so the underlying economics should compound well. But it has fundamentally turned CIC from a pure agribusiness operator into an agribusiness + a stake in another holdco, which is unusual and warrants scrutiny on whether shareholders prefer this structure or would rather have the cash returned.
◆ FRAMEWORK NOTE — APPLYING THE WARTIME / NECESSITY-SECTOR LENS
Through the wartime / chaos-economy lens (necessity consumption, healthcare, defensive sectors, food security): HHL has the best healthcare positioning (hospitals + pharma distribution = essential services). SUN has the best agri-resilience (palm oil = essential calorie source, healthcare exposure). MELS is the contrarian defensive — alcohol consumption is recession-resistant globally; Aitken Spence stake adds maritime/power optionality. CIC has the most direct food-security exposure — Crop Solutions (fertilisers + plant protection) and Livestock are essential agricultural inputs. If the question is "which one offers the most direct exposure to the wartime thesis," CIC is actually the strongest fit operationally — it's just being held back by the balance sheet and accounting concerns.
§08
Vs the LOLC group — what's the difference
Reference back to prior research
For readers who reviewed the LOLC piece — putting all four defensives plus BIL on the same quality tests:
Quality test
BIL (LOLC group)
HHL
SUN
MELS
CIC
Bargain-purchase / FV gain dependency
LKR 54.5B (105% of PBT)
None
Some via biological assets
None material
LKR 5.5B FY24 (40% of PBT) — disclosed as one-off, now rolled off
Op CF / PAT ratio
Trivial (severe flag)
1.61× (excellent)
~2.1× (excellent)
~1.1× (acceptable)
0.67× (below threshold)
TTM EPS aligned with reported
−0.70 vs reported +4.01
Aligned
Aligned
Aligned
Aligned (post roll-off)
Reported margin vs reality
89% net margin (fictional)
7.1% PAT margin (real)
10.9% PAT margin (real)
8.5% PAT margin (real)
7.6% PAT margin (real)
Subsidiary loss disclosures
Multiple
Minor / managed
Lina mfg slowdown
3 closed in FY25
No major subsidiary issues
Balance sheet leverage
Asset/Equity 3.4×
D/E 0.20
D/E 0.30
D/E 0.35
D/E 0.69 (highest in group)
The contrast is sharper now with CIC included. BIL within the LOLC group fails almost every quality-of-earnings test in catastrophic fashion. HHL, SUN and MELS all pass cleanly. CIC sits in a middle category — clearly nothing like BIL (the bargain-purchase was disclosed, one-time, and modest in size; the underlying business has real revenue growth and segment profits) but also clearly not in the top tier of cash-conversion or balance-sheet quality. The CIC dossier is not a "stay away" call; it's a "do more diligence on the receivables build and the JKH stake structure" call.